Definitive Contract 75F40124C00103

Award Date 9/24/24
Potential Completion Date 9/23/27
Potential Value $3.4M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Tampa, FL 33611, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,847,030 delivery order contract awarded by the Food and Drug Administration (FDA) to Battelle Memorial Institute, a nonprofit research and development organization. The contract is for comparative pharmacokinetics and in vivo genetic toxicology studies of N-Nitrosonornicotine (NNN) in rats. The work is being performed under the FDA's "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract has a firm fixed price...
Technical Resources International, Inc. (TRI) has been awarded a firm fixed price purchase order valued at one million six hundred twenty four thousand one hundred twenty two dollars and twenty cents ($1,624,122.20) by the Department of Health and Human Services' Food and Drug Administration (FDA) to assess nicotine dose discrimination in marketed cigarettes. This purchase order was issued under an indefinite delivery/indefinite quantity contract held by TRI with the National Institutes of...
The Department of Health and Human Services Food and Drug Administration awarded a $36,286,201 firm-fixed-price definitive contract to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to conduct a study on the toxicity of e-cigarette aerosol in in vivo nonclinical models. The contract does not have a set-aside designation and is scheduled for completion by February 28, 2025. Vamco, LLC, a small disadvantaged business, was awarded a subcontract to...
The U.S. Food and Drug Administration (FDA) awarded a $653,000.00 firm-fixed-price purchase order to Tamarind Media LIMITED, a for-profit organization based in the United Kingdom. The contract is to provide the FDA with deidentified raw data and information from existing 2015-2019 surveys of U.S. vape shops and consumers, including the "US Vape Store Survey" and the "US Vape Product Consumer Survey" conducted by ECigIntelligence. This requirement supports the FDA's ongoing...
This is a delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit organization, for a project titled "CYTOTOXICITY OF COMMON SOLVENTS USED IN LIQUID NICOTINE FORMULATIONS". The contract has a potential value of $1,149,919.00 and a completion date of April 15, 2021. This delivery order is part of a larger indefinite delivery/indefinite quantity...
This federal contract award from the Food and Drug Administration (FDA) to Battelle Memorial Institute, a nonprofit research and development organization, is for investigating the effects of nicotine pouch flavors on abuse liability in smokeless tobacco users. The $1,923,145.00 firm fixed-price delivery order has a period of performance ending on May 30, 2026. The award does not have a set-aside designation. Battelle has subcontracted with Montrose Environmental Group, Inc., an environmental...
This is a $1,259,043.67 definitive contract awarded by the Food and Drug Administration (FDA) to the National Academy of Sciences (NAS), a non-profit organization, to conduct a study on the health effects of electronic nicotine delivery systems. The contract is for research and technical advisory services, and is not set aside for any specific business type. NAS frequently receives federal contracts and grants to provide expert scientific analysis and policy advice to government agencies...
This is a firm-fixed-price delivery order under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract, awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization. The contract is for studying the effects of menthol on the pharmacokinetics of nicotine and tobacco-specific nitrosamines, with a ceiling value of $1,640,749.00 and...
This is a firm fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $3,872,713 task order is for a study titled "ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS". The work is not set aside. Lovelace has experience supporting the National Institutes of Health (NIH), Department of...
This is a federal contract awarded by the Food and Drug Administration (FDA) to Research Triangle Institute (RTI International), a prominent non-profit research organization, for $813,633.00. The contract is for research on the effects of nicotine salts on the leaching of metals into e-liquids. The contract is a delivery order with a firm fixed price pricing type and an ultimate completion date of January 19, 2027. RTI International has extensive experience working with federal agencies...

This is a Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian agency, to The Fox Foundation Inc., a non-profit organization, for $3,408,203.00. The contract is to conduct a randomized, double-blinded, within-subjects, crossover clinical laboratory study to determine whether abuse liability, as measured by nicotine exposure, subjective measures, and product use behavior, differs between e-liquids formulated with tobacco-derived nicotine (TDN) and non-tobacco nicotine (NTN), and to evaluate ENDS use behavior and nicotine exposure with NTN e-liquids containing varying enantiomeric ratios. The contract has a period of performance of 3 years from the date of award on September 24, 2024, and there is no set-aside designation.

Generated 4/10/25, 11:35 AM